Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
Scott M Rocklage sold 60,956 shares of SKYE on 21 August at $3.57 per share, worth a total of $218K. They now own 1,621,043 SKYE shares, or a 49% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
